Adalimumab inflammatory signaling pathways

Adalimumab Modulates NF-κB, JAK/STAT, TNFα-TGFβ, Notch-1, IL-17, and IL-12/23 Signaling Pathways

Adalimumab modulates multiple interconnected inflammatory signaling pathways through direct TNF-α blockade and subsequent downstream effects. In keratinocytes, adalimumab primarily targets NF-κB signaling by downregulating IKBKB, IRAK1, TRAF2, MAP3K7, and TNFAIP3, with IKBKB functioning as a central hub in protein-protein interaction networks. In T cells, the dominant mechanism involves JAK/STAT pathway modulation, with adalimumab increasing STAT6 phosphorylation and restoring STAT4 activation to healthy levels, while disrupting Th1, Th17, and Th22 pathways in psoriasis patients. Adalimumab also affects the TNFα-TGFβ signaling axis differentially depending on disease context.

Abstract

Adalimumab reduces inflammatory mediator production (CRP, TNF, IL-6, GlycA) and leads to clinical improvements in psoriasis and rheumatoid arthritis, while demonstrating adverse effects on HDL metabolism at 52 weeks. Findings reflect cell type-specific inflammatory network architecture, indicating that adalimumab is most effective when TNFα drives downstream inflammatory cascades.

Methods

We analyzed 10 sources from an initial pool of 200 papers using 8 screening criteria relevant to adalimumab's effects on inflammatory pathways. These included inflammatory pathway focus, mechanistic outcomes, patient population, and publication type.

Paper Search

A semantic search across over 138 million academic papers returned 200 results.

Screening Criteria

• Inflammatory Pathway Focus
• Mechanistic Outcomes
• Adalimumab Study Population
• Study System Type
• Pathway Analysis Inclusion
• Adalimumab-Specific Data
• Single Intervention Analysis
• Publication Type

Data Extraction Parameters

• Study Context: Cell type, disease model, experimental system, inflammatory stimulus.
• Inflammatory Pathways: Pathway names, components, interactions.
• Adalimumab Treatment: Concentration, duration, administration route, schedule.
• Pathway Modulation: Direction of effect, magnitude, specific components.
• Molecular Mechanisms: Direct vs. indirect effects, interactions, gene expression changes, microRNA involvement.
• Measurement Methods: Assays, gene expression techniques, validation approaches.
• Functional Outcomes: Cytokine production changes, effects on cell function, clinical improvements, biomarker changes, adverse effects.

Results

Characteristics of Included Studies

Inflammatory Pathways Modulated by Adalimumab

NF-κB Signaling Pathway

Adalimumab reversed LPS-induced upregulation of multiple NF-κB-associated genes and validated its effects at both mRNA and protein levels. Gene ontology revealed enrichment in immune regulation and NF-κB signaling pathways.

JAK/STAT Signaling Pathway

In the JAK/STAT pathway, adalimumab affected 18 of 37 mRNAs associated with this pathway. It increased Th2-associated STAT6 phosphorylation and restored Th1-associated STAT4 phosphorylation.

TNFα-TGFβ Signaling Axis

In juvenile idiopathic arthritis synoviocytes, adalimumab demonstrated differential effects, with persistent FLS showing upregulation of TNFα and TGFβ, while ETB FLS exhibited decreased TGFβ.

Notch-1 Signaling Pathway

In inflammatory bowel disease, Notch-1 mediated the inhibitory effects of adalimumab on T cell cycling, showcasing the importance of pathway-specific modulation.

Functional Outcomes

Adalimumab consistently reduced key inflammatory markers across studies. Changes in cytokine production were seen in psoriasis patients treated with adalimumab, with adverse effects including changes in lipid metabolism noted at 52 weeks.

Synthesis

In summary, understanding the pathway-specific and temporal dynamics of adalimumab's action underscores its clinical utility while demonstrating the need for tailored patient management based on individual inflammatory profiles.